Ritter Sport USA, Inc. Partners with ReposiTrak to Proactively Deliver Outbound Food Traceability Data to U.S. Retailers
WALDENBUCH, Germany & SALT LAKE CITY--(BUSINESS WIRE)--Ritter Sport USA, Inc., the beloved German chocolate brand known for its iconic square bars and commitment to sustainability, has joined the ReposiTrak Traceability Network® to share outbound food traceability data with its current and future U.S. retail customers. Ritter Sport is taking a forward-focused approach to traceability, as major retailers and wholesalers now require more extensive data for a wider range of foods than what is mandated by the FDA's FSMA 204 food traceability final rule.
'Our decision to improve product traceability was driven by our commitment to doing what's right for our customers – both retail partners and the shoppers they serve,' said Ralf Hilpuesch, CEO of Ritter Sport USA. 'ReposiTrak enables us to proactively deliver the most complete and accurate food traceability data through a single, centralized platform. This step reflects our dedication to food safety, product integrity and transparency in every chocolate square we produce.'
The ReposiTrak Traceability Network is the industry's largest and fastest-growing platform for food traceability, enabling seamless data sharing between suppliers and retailers without the need for additional hardware, software or manual effort. Ritter Sport will utilize the network to deliver traceability data to its U.S. retail partners for every outbound shipment – enhancing transparency and collaboration across the supply chain.
'Ritter Sport is leading by example,' said ReposiTrak Chairman and CEO Randy Fields. 'They're setting a precedent for food manufacturers around the world – taking on traceability because it's the right thing for their customers and because the FDA has signaled that the FTL will only grow from here. That's the kind of leadership that will shape the future of food traceability.'
Ritter Sport's decision to voluntarily share traceability data exemplifies a growing movement among food manufacturers to prioritize safety, build trust and modernize operations – regardless of regulatory mandates.
With this integration, Ritter Sport gains the ability to:
Share outbound traceability data with its current and future U.S. retail customers
Streamline supply chain communications and reduce response time in the event of a recall or investigation
Strengthen customer relationships through transparency and accountability
In addition to openly sharing traceability data with retailer partners, Ritter Sport is committed to sustainability and ethical sourcing across the entire supply chain, aiming to trace 100% of its cocoa back down to the farming organization by 2025.
To learn more about Ritter Sport, visit www.ritter-sport.com /en. For more information about the ReposiTrak Traceability Network, visit www.repositrak.com.
About Ritter Sport
Established in 1912, Ritter Sport is a fourth-generation, family-owned company known for its signature square-shaped German chocolate, quality ingredients, vibrant snap-open packaging and commitment to sustainability. Ritter Sport's mission is to do the right thing to create really good chocolate and is the first major chocolate bar manufacturer to source 100% certified cocoa through its El Cacao programs and farmer partnerships. To learn more about Ritter Sport, visit www.ritter-sport.com/en.
ReposiTrak (NYSE: TRAK) provides retailers, suppliers and wholesalers with a robust solution suite consisting of three product families: food traceability, compliance and risk management and supply chain solutions. ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit www.repositrak.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation. Orphan drug designation is granted by the FDA to therapies intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the United States. The goal is to encourage drug development for rare diseases or conditions by offering incentives such as tax credits for clinical testing, waiver of certain fees and most importantly, seven years of market exclusivity upon approval. For Sanofi, this designation provides riliprubart with important regulatory and financial advantages as it advances through clinical development for AMR in solid organ transplantation — a serious complication where the immune system attacks the donated organ. Currently, there are no FDA-approved therapies for this condition. The designation may help accelerate progress and reduce the development burden as Sanofi works to address this critical unmet need in transplant medicine. Shares of Sanofi have outperformed the industry year to date, as seen in the chart below. Image Source: Zacks Investment Research An investigational IgG4 humanized monoclonal antibody, riliprubart is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system. The drug is currently being evaluated in a mid-stage study for AMR in kidney transplant recipients across two patient groups — those at risk of developing rejection and those already experiencing active AMR. Apart from AMR, Sanofi is also evaluating riliprubart in two late-stage studies — MOBILIZE and VITALIZE — for a rare neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP). While the MOBILIZE study targets patients for whom standard-of-care treatments do not work, the VITALIZE study compares the drug against intravenous immunoglobulin (IVIg). CIDP is a rare disorder affecting the peripheral nervous system, marked by progressive muscle weakness and sensory loss. Notably, riliprubart has also received orphan drug designation in both the United States and EU for its prospective use in CIDP, highlighting its potential across multiple immune-mediated diseases. Sanofi currently carries a Zacks Rank #3 (Hold). Sanofi price | Sanofi Quote Some better-ranked stocks from the sector are Amarin Corporation AMRN, Immunocore IMCR and Agenus AGEN. While AMRN and IMCR sport a Zacks Rank #1 (Strong Buy) each at present, AGEN carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Amarin's 2025 have improved from $5.01 to $2.50. Loss per share estimates for 2026 have narrowed from $3.84 to $1.78 during the same period. AMRN stock has surged nearly 65% year to date. Amarin's earnings beat estimates in two of the trailing four quarters, met the mark once and missed in the other, delivering an average surprise of 29.11%. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained nearly 9% year to date. Immunocore's earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%. In the past 60 days, Agenus' bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 83% so far this year. Agenus' earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
10 hours ago
- Business Upturn
Viscosupplementation Market Size to Reach USD 11.37 Billion by 2032 Owing to Rising Geriatric Population and Growing Osteoarthritis Incidence
Austin, June 29, 2025 (GLOBE NEWSWIRE) — Viscosupplementation Market Size & Growth Analysis: 'According to SNS Insider, the global Viscosupplementation Market was valued at USD 5.48 billion in 2024 and is expected to reach USD 11.37 billion by 2032, expanding at a CAGR of 9.56% over the forecast period of 2025–2032.' Growing need for minimally invasive osteoarthritis treatment, favourable reimbursement policies, and increasing incidence of knee disorders would contribute to the adoption of viscosupplementation worldwide. Get a Sample Report of Viscosupplementation Market@ U.S. viscosupplementation market was valued at USD 1.21 billion in the year 2024 and is estimated to reach USD 2.50 billion by the year 2032. This expansion is a result of growing FDA approvals, strong presence of key manufacturers, and high adoption of three-injection therapy for osteoarthritis patients in both orthopedic clinics and ambulatory surgical centers. Market Overview The viscosupplementation market is growing leaps and bounds as a result of the increasing population with osteoarthritis, especially in the older age segment across the world. As awareness of alternative pain treatments, e.g., minimally invasive, continues to increase, so does the request for hyaluronic acid (HA) injections that are able to restore the viscosity of the damaged synovial fluid in the joints. The treatment has been widely adopted because it is associated with short recovery time, fewer side effects, and more patient satisfaction. In addition, the feasibility of having single- or multiple-injection regimens available facilitates individual treatment planning according to patient preference and extent of disease. North America dominates the market on account of well-established healthcare infrastructure, increasing adoption across the region, and continued development. At the same time, Asia Pacific is set to be the fastest-growing region on account of the rising accessibility to healthcare, the growing number of orthopedic procedures, and increasing awareness of viscosupplementation. Efforts by the governments of countries like Japan, China, and India to enhance geriatric care are also driving growth in the region. Major Players Analysis Listed in this Report are: DePuy Synthes Fidia Farmaceutici S.p.A Sanofi Smith & Nephew PLC Anika Therapeutics, Inc. Seikagaku Corp. Zimmer Biomet Ferring Pharmaceuticals B.V. Lifecore Biomedical LG Life Sciences Ltd. Roche Ltd. Viscosupplementation Market Report Scope Report Attributes Details Market Size in 2023 US$ 5.48 billion Market Size by 2032 US$ 11.37 billion CAGR (2024–2032) 9.56% U.S. Market 2023 USD 1.21 billion U.S. Forecast by 2032 USD 2.50 billion Base Year 2023 Forecast Period 2024–2032 Key Regional Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis By Product: The three-injection viscosupplementation segment held the largest market share in 2023, accounting for 42%. This dominance is attributed to its proven long-term efficacy in moderate-to-severe osteoarthritis cases, offering sustained pain relief and improved mobility. Physicians widely prefer this format due to its extensive clinical validation and familiarity. Meanwhile, the single-injection segment is the fastest-growing product type. Its rapid adoption is driven by increased patient compliance, reduced clinic visits, and lower procedural costs. These benefits are especially appealing in outpatient and resource-constrained settings. By End-Use: In 2023, orthopedic clinics and ambulatory surgical centers (ASCs) led the market, contributing 63% of the overall revenue. The rise of outpatient care models, availability of advanced orthopedic expertise, and focus on cost-effective joint pain management have supported this segment's dominance. Conversely, hospitals are the fastest-growing end-use segment due to the rise in inpatient osteoarthritis treatment, complex case management, and integration of viscosupplementation into broader rehabilitation programs, particularly for elderly and comorbid patients. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Viscosupplementation Market Segmentation By Product Three Injection Single Injection Five Injection By End-use Hospitals Orthopedic Clinics/ASCs Regional Analysis North America held the largest share of the viscosupplementation market in 2024, driven by a high osteoarthritis patient base, favorable insurance coverage, and strong regulatory backing for HA-based injectables. The U.S. continues to dominate due to established clinical protocols and patient preference for minimally invasive alternatives. Asia Pacific is the fastest-growing regional market, propelled by increasing healthcare expenditure, improving patient awareness, and rapid urbanization. Growing demand in China, Japan, and India is further stimulated by efforts to reduce surgical interventions through conservative treatment options. Recent Developments In January 2024, Zimmer Biomet launched a new three-injection viscosupplementation product in select global markets targeting moderate-stage osteoarthritis. In February 2024, Sanofi announced the rollout of its improved formulation of hyaluronic acid injections across Europe, aimed at extending joint relief duration. In March 2024, the U.S. FDA approved multiple new single- and three-injection HA-based viscosupplementation products, enhancing treatment availability. In April 2024, Seikagaku Corporation reported over 2 million units of viscosupplementation products distributed globally during the first half of 2024. Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Viscosupplementation Market by Product 8. Viscosupplementation Market by End-use 9. Regional Analysis 10. Company Profiles 11. Use Cases and Best Practices 12. Conclusion Buy a Single-User PDF of Viscosupplementation Market Analysis & Outlook Report 2024-2032@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
10 hours ago
- Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
